Intracoronary Adenosine Administration to Prevent Periprocedural Myonecrosis in Elective Coronary Angioplasty
NCT ID: NCT01148147
Last Updated: 2011-11-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
260 participants
INTERVENTIONAL
2009-11-30
2010-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a double-blind randomized trial single-center study. The enrollment will last 10 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Intracoronary Placebo administration
Placebo
Intracoronary Placebo administration
Adenosine
Intracoronary adenosine administration
Adenosine
Intracoronary adenosine administration (180 ug for LCA and 120 ug for RCA)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Adenosine
Intracoronary adenosine administration (180 ug for LCA and 120 ug for RCA)
Placebo
Intracoronary Placebo administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Previous allergy to adenosine
* Inability to sign the informed consent
* Asthma
* Elevated cardiac enzymes (troponin I o CK-MB)
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Azienda Ospedaliero Universitaria Maggiore della Carita
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AOU Maggiore della Carita - Eastern Piedmont University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Giuseppe De Luca, MD
Role: PRINCIPAL_INVESTIGATOR
AOU Maggiore della CaritÃ
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Giuseppe De Luca
Novara, , Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
De Luca G, Iorio S, Venegoni L, Marino P. Evaluation of intracoronary adenosine to prevent periprocedural myonecrosis in elective percutaneous coronary intervention (from the PREVENT-ICARUS Trial). Am J Cardiol. 2012 Jan 15;109(2):202-7. doi: 10.1016/j.amjcard.2011.08.027. Epub 2011 Oct 14.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-013681-92
Identifier Type: REGISTRY
Identifier Source: secondary_id
CE 93/09
Identifier Type: -
Identifier Source: org_study_id